GLP-1 agonist medications — including widely prescribed drugs such as Ozempic, Wegovy, and Mounjaro — have been associated with an approximately 30% reduction in the risk of developing breast cancer in women, according to an observational study presented this week at the world's largest oncology conference. The research, which analyzed health records from more than 110,000 patients, was unveiled at the 2026 meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in the journal JCO Oncology Practice on Tuesday. While the findings indicate a statistically promising correlation, the study authors emphasized that deeper investigations are essential to confirm whether these drugs can actually prevent the disease. The data suggest a potential new avenue for breast cancer prevention, but the researchers caution against overinterpreting the results at this stage.
Study Methodology and Key Findings
Led by Dr. Elizabeth McDonald, a professor of Radiology at the Perelman School of Medicine at the University of Pennsylvania, the research team examined medical records from 111,646 women aged 45 to 80 who had a body mass index of 25 or higher and underwent breast imaging at Penn Medicine between January 2022 and June 2025. Among them, 15,264 patients — representing 13.7% — had active prescriptions for GLP-1-based drugs, while the remaining 96,382 had no recorded exposure to these medications. To minimize bias, the scientists assessed new tumor diagnoses using two analytical approaches. In the full population sample, users of the drugs showed a 35.1% lower probability of developing breast cancer. In a matched group of 30,528 women, paired by age, race, ethnicity, BMI, breast density, and diabetes status, the confirmed reduction was 30.5%.
Biological Mechanisms Beyond Weight Loss
The observed preventive benefits may extend beyond the well-established role of weight loss in reducing breast cancer risk, particularly for postmenopausal women. Scientists suspect that additional biological pathways are at play, as these substances mimic the natural GLP-1 hormone and work to lower chronic low-grade inflammation through multiple cellular mechanisms. The drugs also regulate overall metabolism and alter epigenetic processes that directly control gene activity, potentially suppressing the early development of tumor cells. These parallel effects could explain why the risk reduction persists even after accounting for weight loss alone. However, the researchers stress that these mechanisms remain theoretical and require experimental validation.
Limitations and Researcher Cautions
Despite the promising metrics, the study's authors emphasized structural limitations that prevent definitive conclusions. The analysis did not differentiate the performance of specific drug brands, mixing data for semaglutide and tirzepatide together. Additionally, it did not account for the continuous duration of treatment, hereditary genetic risk factors, the stage of cancer at diagnosis, or the tumor subtype. Further analyses are planned to examine the influence of some of these variables on the observed results. The researchers warned that the findings represent a statistical correlation, not proof of causation.
Plans for Future Clinical Trials
Dr. McDonald confirmed that her team is planning a multicenter clinical trial specifically targeting high-risk women to determine whether GLP-1-based drugs can actually prevent the onset of breast cancer. Currently, options for mitigating breast cancer risk in predisposed patients are limited to frequent screenings, prophylactic mastectomy, or the continuous use of Tamoxifen — a medication often rejected by patients due to severe side effects. "Ultimately, we want to find better options to prevent breast cancer," McDonald stated in a press release. "It has been encouraging to see survival rates improve over the past decades, and we would love to see the same gains in prevention." These future trials will aim to provide the causal evidence that the current observational study cannot offer.
Implications for Cancer Prevention
Originally developed to treat type 2 diabetes and later approved for weight management, these medications are now being investigated for their potential repurposing as tools for cancer prevention. The scientific community is watching closely, as a successful clinical trial could transform the landscape of breast cancer prevention for millions of women. However, the researchers reiterate that the current data point only to a statistical association and that longer-term patient follow-up studies are necessary. This study represents an important step forward, but it remains far from providing a definitive answer. The path from these observational findings to a clinical recommendation is long and requires robust evidence of causality.